Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.70 USD
Change Today +0.10 / 3.85%
Volume 76.4K
ONTX On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

onconova therapeutics inc (ONTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/19/14 - $5.78
52 Week Low
02/18/15 - $2.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

onconova therapeutics inc (ONTX) Related Businessweek News

No Related Businessweek News Found

onconova therapeutics inc (ONTX) Details

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company’s clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates that target kinases, cellular metabolism, or cell division in preclinical development. It has a development and license agreement with Baxter Healthcare SA; and a license agreement with SymBio Pharmaceuticals Limited. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.

38 Employees
Last Reported Date: 05/15/15
Founded in 1998

onconova therapeutics inc (ONTX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $713.4K
Chief Financial Officer and Secretary
Total Annual Compensation: $347.9K
President of Research and Development
Total Annual Compensation: $450.7K
Senior Vice President of Product Development
Total Annual Compensation: $465.5K
Compensation as of Fiscal Year 2014.

onconova therapeutics inc (ONTX) Key Developments

Onconova Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Onconova Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's revenue was $114,000 compared to $447,000 a year ago. Loss from operations was $12,349,000 compared to $18,733,000 a year ago. Net loss was $12,367,000 compared to $18,716,000 a year ago. Net loss attributable to the company was $12,343,000 compared to $18,679,000 a year ago. Net loss per share of common stock, basic and diluted was $0.57 compared to $0.87 a year ago.

Onconova Therapeutics, Inc., Annual General Meeting, Jun 15, 2015

Onconova Therapeutics, Inc., Annual General Meeting, Jun 15, 2015., at 10:00 Eastern Daylight. Location: offices of Pepper Hamilton LLP. Agenda: To elect seven directors, each to hold office until his or her successor is elected and qualified at the 2016 Annual Meeting of Stockholders; to consider and take action on the ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal 2015; and to transact such other business as may properly come before the meeting or any adjournments thereof.

Onconova Therapeutics, Inc. Submits Pivotal Clinical Trial Protocol for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes to FDA and EMA

Onconova Therapeutics, Inc. announced that the Company has submitted a protocol for a global pivotal study of IV rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) for whom prior treatment with approved hypomethylating agents has failed for regulatory review. Parallel submissions were made to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The new Phase 3 randomized controlled trial of IV rigosertib derives from the findings of the ONTIME trial and is based on guidance received from previous consultations with FDA and EMA. The protocol includes a subgroup of HR-MDS patients, identified from an analysis of the ONTIME trial, who demonstrated an encouraging improvement in overall survival compared to the control arm. Based on previous guidance received from both FDA and EMA, and following discussions with key opinion leaders in the U.S. and Europe, the proposed primary endpoint for the new trial is overall survival. Additional details of the trial design and plan, including postings on national clinical trials registration databases, will be available following completion of the regulatory review processin the U.S. and Europe. Pending regulatory review and appropriate financing, international clinical trial sites are expected to be opened for enrollment into this new study during the second half of 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTX:US $2.70 USD +0.10

ONTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONTX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ONTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 110.1x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 36.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCONOVA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at